Nephrol Dial Transplant (2004) 19: 1-5
© ERA–EDTA 2003; all rights reserved
Editorial Comment
What is the role of albumin in proteinuric glomerulopathies?
Department of Nephrology, University Hospital, Lund, Sweden
Correspondence and offprint requests to: Professor Bengt Rippe, Department of Nephrology, University Hospital of Lund, S-211 85 Lund, Sweden. Email: Bengt.Rippe@njur.lu.se
Keywords: albumin; capillary permeability; endothelium; glomerular filtration; glycocalyx; proteinuria
| The first 150 words of the full text of this article appear below. |
 |
Introduction |
|---|
Albumin is a 69 kDa plasma protein (molecular radius
36 Å) with a variety of functions, including maintenance of plasma oncotic pressure, buffering of plasma acid–base changes and functioning as a transport protein for hormones, fatty acids, phospholipids, ions and heavy metals [1]. Albumin was early identified as critical in regulating endothelial permeability, especially in studies on single perfused microvessels [2]. Later, plasma acidic glycoproteins, especially orosomucoid, were found to be (additional) crucial factors in maintaining normal microvascular permeability, particularly to negatively charged macromolecules (e.g. albumin) [3]. The critical role of albumin and orosomucoid in maintaining vascular permeability has also been demonstrated for glomerular capillaries [4,5]. Paradoxically, in Nagase analbuminaemic rats (NARs), a mutant of the Sprague–Dawley strain devoid of circulating albumin, the clearance of proteins (albumin and IgG) to the interstitium was, however, only moderately increased [6]. |
Determinants of normal glomerular permselectivity |
|---|
|
Normal capillary permselectivity is dependent on interactions of the endothelium with plasma |
|---|
|
The role of albumin in the progression of glomerular disease |
|---|
|
Conclusion |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Minutolo, P. Chiodini, B. Cianciaruso, A. Pota, V. Bellizzi, D. Avino, S. Mascia, S. Laurino, V. Bertino, G. Conte, et al. Epoetin Therapy and Hemoglobin Level Variability in Nondialysis Patients with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 552 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S Shord, J.M. Hamilton Jr, and S. Cuellar Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia Journal of Oncology Pharmacy Practice, March 1, 2008; 14(1): 5 - 22. [Abstract] [PDF]
|
|
|
|
 |
|
 L. A Calo, P. A Davis, E. Pagnin, L. Bertipaglia, A. Naso, A. Piccoli, R. Corradini, M. Spinello, V. Savica, and L. D. Libera Carnitine-mediated improved response to erythropoietin involves induction of haem oxygenase-1: studies in humans and in an animal model Nephrol. Dial. Transplant., March 1, 2008; 23(3): 890 - 895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Girndt, P. Stenvinkel, C. Ulrich, J. Axelsson, L. Nordfors, P. Barany, J. J. Carrero, G. H. Heine, H. Kaul, and H. Kohler Influence of cytokine gene polymorphisms on erythropoetin dose requirements in chronic haemodialysis patients Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3586 - 3592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. West, K. Harris, M. S. Gilthorpe, C. Tolman, and E. J. Will Functional Data Analysis Applied to a Randomized Controlled Clinical Trial in Hemodialysis Patients Describes the Variability of Patient Responses in the Control of Renal Anemia J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2371 - 2376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-C. Szeto, K.-M. Chow, C.-B. Leung, B. C.-H. Kwan, K.-Y. Chung, M.-C. Law, and P. K.-T. Li Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1697 - 1702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-L. Koepke, M. Weber, E. Schulze-Lohoff, B. Beirowski, S. Segerer, and O. Gross Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1062 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Guz, G. L. Glorieux, R. De Smet, M.-A. F. Waterloos, R. C. Vanholder, and A. W. Dhondt Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2834 - 2840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Carrera, L. Oliveira, P. Maia, T. Mendes, and C. Ferreira The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2846 - 2850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Papavasiliou, C. Gouva, K. C. Siamopoulos, and A. D. Tselepis PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1270 - 1277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Yu, R. M. Sandoval, and B. A. Molitoris Quantitative intravital microscopy using a Generalized Polarity concept for kidney studies Am J Physiol Cell Physiol, November 1, 2005; 289(5): C1197 - C1208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Jadoul Optimal care of lupus nephritis patients Lupus, January 1, 2005; 14(1): 72 - 76. [Abstract] [PDF]
|
|
|
|
|
|
T. M. Osicka, K. J. Strong, D. J. Nikolic-Paterson, R. C. Atkins, and W. D. Comper Albumin and glomerular permselectivity Nephrol. Dial. Transplant., February 1, 2004; 19(2): 511 - 512. [Full Text] [PDF]
|
|